---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-380184"
form_type: "8-K"
ticker: "SCTX"
cik: "0001853921"
company_name: "Scribe Therapeutics, Inc."
filed_at: "2026-09-02T20:08:19+00:00"
generated_at: "2026-09-02T20:10:17.461981+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Scribe Therapeutics Q2 2026 net loss $6.5M; cash $43M plus $140.6M IPO proceeds fund to H1 2029

## Summary
- Q2 net loss $6.5M ($2.62/share) vs $9.9M ($4.08) YoY; collaboration revenue $1.9M vs $4.9M.
- Cash & marketable securities $43.0M at 6/30/26; July IPO + Sanofi placement raised $155.5M gross, $140.6M net.
- Initiated first-in-human Phase 1 of STX-1150 (PCSK9 epigenetic silencing); NHP data showed up to 68% LDL-C reduction.
- Awarded ~$25.7M CIRM grants: $12.7M for STX-1200 (Lp(a)), $13.0M for STX-1400 (triglycerides).
- R&D expenses fell to $8.8M from $13.9M; management expects run-rate funding into H1 2029.

## SEC filing metadata
- accession: 0001193125-26-380184
- form_type: 8-K
- ticker: SCTX
- cik: 0001853921
- company_name: Scribe Therapeutics, Inc.
- filed_at: 2026-09-02T20:08:19+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1853921/000119312526380184/0001193125-26-380184-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1853921/000119312526380184/sctx-20260902.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-380184
- JSON: https://secwatch.observer/filing/0001193125-26-380184.json
- Plain text: https://secwatch.observer/filing/0001193125-26-380184.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.
